Apomorphine is a morphine derivative D2 dopamine agonist used to treat hypomobile "off" episodes of advanced Parkinson's disease. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.
- Mechanism
- Curator reviewed · 5 references
Apomorphine is a non-ergoline dopamine agonist with high binding affinity to dopamine D2, D3, and D5 receptors. Stimulation of D2 receptors in the caudate-putamen, a region of the brain responsible for locomotor control, may be responsible for apomorphine's action. However, the means by which the cellular effects of apomorphine treat hypomobility of Parkinson's remain unknown.
- Primary indication
- Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.Curator reviewed · 1 structured indication
- Formula / weight
- C17H17NO2 · 267.3224 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2004
- Code names
- APL-130277 · VR-040 · VR-400
- Brand names
Resolves to
VMWNQDUVQKEIOC-CYBMUJFWSA-NSMILES[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23What you can answer from here — as of September 12, 2026
Which drugs share a target with Apomorphine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account